Business Context and Reporting Period
This Form 8-K was filed by eFoodsafety.com, Inc. (not Pharmacyte Biotech, Inc.) on February 11, 2009. The registrant is a Nevada holding company focused on health technologies. The report details a material definitive agreement entered into on February 11, 2009, with Charlston Kentrist 41 Direct, Inc. (CK-41) regarding the restructuring of a marketing agreement for the purEffect acne treatment system.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The transaction involves the following specific financial terms:
- Asset Transfer: eFoodsafety.com transferred all rights to purEffect to CK-41.
- Equity Consideration: eFoodsafety.com received 4,250,000 shares of CK-41 common stock valued at $0.01 per share.
- Warrant Grant: eFoodsafety.com received a three-year warrant to purchase an additional 4,250,000 shares of CK-41 common stock at $6.00 per share.
- Royalty Rights: eFoodsafety.com retains a 2% royalty on worldwide adjusted gross sales of purEffect.
- Minimum Royalty Payments: $150,000 due March 1, 2010, and $250,000 due March 1, 2011.
- Board Representation: eFoodsafety.com secured one seat on the CK-41 board of directors.
Material Changes and Default Provisions
The agreement includes specific default triggers related to CK-41's ability to secure financing and meet obligations. If CK-41 fails to meet these conditions, eFoodsafety.com may terminate the agreement and reclaim the product rights.
- Financing Milestones: CK-41 must obtain at least $2.0 million in equity financing by April 1, 2009, and an additional $5.0 million by September 1, 2009.
- Other Defaults: Failure to meet minimum royalty obligations or filing for bankruptcy (voluntary or involuntary).
- Cure Period: CK-41 has 39 calendar days to cure a default after receiving written notice from eFoodsafety.com.
Outlook, Risks, and Management Commentary
Management describes CK-41 as a leading producer of direct response infomercial campaigns with 50 years of industry expertise. The primary risk identified is CK-41's failure to secure the requisite equity financing ($2.0 million and $5.0 million tranches) within the specified timelines, which would trigger default provisions. The filing does not provide forward-looking guidance on eFoodsafety.com's overall financial outlook beyond this specific transaction.
Key Facts for Investor Verification
- Verify the current market value and liquidity of the 4,250,000 CK-41 shares received.
- Confirm whether CK-41 met the $2.0 million equity financing deadline of April 1, 2009.
- Assess the likelihood of CK-41 meeting the subsequent $5.0 million financing target by September 1, 2009.
- Monitor the status of the minimum royalty payments due in 2010 and 2011.
- Note the discrepancy between the requested company name (Pharmacyte Biotech) and the actual registrant (eFoodsafety.com, Inc.).